What is CRVO's market cap?

$23.59M, based on the Nov 4 close of $1.56.

Does CervoMed pay a dividend?

No regular cash dividend has been paid in the last year.

How much of CRVO is sold short?

1.2M shares, 12.7% of float, as of Oct 15, 2026.

What sector is CRVO in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · CRVOHealthcarePharmaceuticals

CervoMed Inc. Common Stock (CRVO)

$1.56+0.65%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.56▼ 77.78% in range

Nov 4, 2025Low $1.55 · High $9.94Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

CervoMed closed at $1.56 on Nov 4, up 0.65%, within 0.6% of its 52-week closing low. Volume of 428.8K shares was 1.30× its 20-day average (above normal).

Split-adjusted performance: -53.3% over one month, -59.3% over six months, -77.8% over one year.

Short interest was 1.2M shares at the Oct 15 settlement, down 9.8% from the prior report (12.7% of float, 3.0 days to cover).

Market cap$23.6M15.1M shares

Revenue · quarter$0.00−100.0% YoY

Diluted EPS$-0.64—

P/E · TTM—P/S 71.2×

Net margin—

Dividend yieldNone

52-week range1.55 – 9.94−84.3% from high

Volume428.8K1.30× 20-day avg

Volatility · 60d88.5%Annualised

Short % of float12.7%3.0 days to cover

Net cash$24.9MCash $24.9M

Next earnings—Not scheduled

Split-adjusted performance

1W −29.4%1M −53.3%3M −43.5%6M −59.3%YTD −80.3%1Y −77.8%3Y −81.8%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum19

Revenue growth4

Net margin—

Value (low P/E)—

Size23

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short1.2M−9.8% vs prior

Days to cover3.0Settled Oct 15

% of float12.7%

Short vol. 10d47.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
CRVOCervoMed	$1.56	+0.65%	−59.3%	−100.0%	—	—	$23.6M
MIRAMIRA Pharmaceuticals	$0.5610	+8.34%	−43.9%	—	—	—	$23.6M	Compare
SHPHShuttle Pharmaceuticals Holdings	$5.21	+1.17%	−33.2%	—	—	—	$24.8M	Compare
CPHIChina Pharma Holdings	$0.5875	−3.56%	+11.4%	−7.5%	−153.8%	—	$25.3M	Compare
CELUCelularity	$0.8088	−1.02%	−13.0%	−5.3%	10.1%	—	$26.2M	Compare
ATOSAtossa Therapeutics	$2.12	−9.01%	−63.4%	—	—	—	$21.2M	Compare
TXMDTherapeuticsMD	$1.82	+2.25%	−10.3%	−8.7%	17.8%	—	$21.1M	Compare
MCRBSeres Therapeutics	$2.09	+6.63%	−73.9%	—	622.4%	—	$21.0M	Compare
EDSAEdesa Biotech	$2.17	−4.82%	−85.5%	—	—	—	$20.9M	Compare

News about CervoMed

All news →

No recent articles focused on CervoMed.

Quick answers

What does CervoMed do?: CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders.
What is CRVO's market cap?: $23.59M, based on the Nov 4 close of $1.56.
Does CervoMed pay a dividend?: No regular cash dividend has been paid in the last year.
How much of CRVO is sold short?: 1.2M shares, 12.7% of float, as of Oct 15, 2026.
What sector is CRVO in?: Healthcare, in the Pharmaceuticals industry.

About CervoMed

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

HQ: Boston, MA15 employeesListed Jun 18, 1996cervomed.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology